The NSABP has long been a leader in designing & conducting advanced Phase II & III #ClinicalTrials. Our clinical trials have reduced extensive surgical procedures, improved neoadjuvant & adjuvant treatment options & ushered in #precisionmedicine. Learn more: nsabp.org
About us
Partners in Cancer Research… The NSABP Foundation is a not-for-profit academic research organization with a nearly 60-year history of conducting ground-breaking research studies in breast and colorectal cancer. Our goal is to improve outcomes for cancer patients via improved therapeutic and prevention modalities. Over the past 15 years we have established full-service capabilities to conduct independently funded international research with the private sector to evaluate promising new agents and now offer a wide range of capabilities, from pre-clinical research through phase III clinical trials focused on biomarker-driven studies. In its history the NSABP has enrolled more than 110,000 women and men in clinical trials in breast and colorectal cancer. We have research sites at nearly 700 major medical centers, university hospitals, large oncology practice groups, and health maintenance organizations in the United States, Canada, and Ireland. At those sites and their satellites, about 5000 physicians, nurses, and other medical professionals conduct NSABP treatment and prevention trials. The NSABP Foundation, located at Nova Place in Pittsburgh, Pennsylvania, carries on the legacy of the National Surgical Adjuvant Breast and Bowel Project in clinical studies done in partnership with industry.
- Website
-
http://www.NSABP.org
External link for NSABP Foundation Inc.
- Industry
- Research Services
- Company size
- 51-200 employees
- Headquarters
- Pittsburgh, PA
- Type
- Nonprofit
- Specialties
- Breast Cancer, Colorectal Cancer, Clinical Trials, and Clinical Trial Research
Locations
-
Primary
Get directions
2 Allegheny Center
Nova Tower, Suite 1200
Pittsburgh, PA 15212, US
Employees at NSABP Foundation Inc.
Updates
-
April is National Cancer Prevention and Early Detection Month. Now more than ever, cancer screenings are of the utmost importance. Learn more: https://lnkd.in/eth7VvJ8
-
-
Today is the last day for #colorectalcancerawarenessmonth, but that doesn’t mean awareness stops. #Colorectalcancer is the 3rd most diagnosed cancer in the US. Get regularly checked starting at age 45 if at average risk.
-
-
Today is #NationalDoctorsDay! Thank you to all the doctors & researchers who help us design & conduct #clinicaltrials to improve the standard of care for patients with cancer. #Gratitude #DoctorsDay
-
-
Did you know that #colorectalcancer rates continue to rise for those under the age of 50? Recommended screening now starts at age 45 for people at average risk. #getscreened #colorectalcancerawarenessmonth
-
-
The NRG-BR009 OFSET #clinicaltrial is enrolling premenopausal patients with early-stage, HER2-negative #breastcancer that is sensitive to hormones & have an Oncotype DX Recurrence Score <= 25. Learn more in the latest episode The NRG Oncology Podcast! NRG ONCOLOGY Stephen Chun Lauren Henke, MD, MSCI
NOW LIVE! Tune in to listen to the latest NRG Oncology podcast episode discussing in-depth the NRG-BR009 study, aka the 'OFSET' study for premenopausal, ER+/HER2- breast cancer patients who are at high risk of the cancer returning as well as the importance of screening early. https://lnkd.in/eEM34-yv
-
-
NSABP history – Dr. Bernie Fisher was appointed chair of the National Surgical Adjuvant Breast and Bowel Project in 1967. Learn more about Dr. Fisher’s legacy: http://ow.ly/IVeI50N0y1X #colorectalcancerawarenessmonth
-
-
A colonoscopy can prevent colorectal cancer by finding polyps before they turn into cancer. Talk with your doctor about when to start regular screenings. #colorectalcancerawarenessmonth #getscreened
-
-
As spring begins, we’re reminded that progress in cancer research is built on persistence, collaboration & hope. Every study, every discovery & every patient who participates in #clinicaltrials brings us one step closer to better treatments and brighter futures.
-
-
Tune in next week to learn more about the NRG-BR009 OFSET #clinicaltrial which is trying to determine whether the chance of #breastcancer returning would be less if chemotherapy is added to hormonal therapy with an aromatase inhibitor & ovarian function suppression.
MARCH 25TH - The NRG Oncology Podcast will be looking at all things breast cancer. During this episode we talk to BR009's co-protocol officers regarding this currently enrolling study for premenopausal, ER+, HER2- breast cancer patients with a high risk of recurrence. We also discuss the importance of screening from Dr. Massarotti who unexpectedly found herself a "physician turned patient" via her cancer diagnosis at a young age. Figure out how to follow: https://lnkd.in/eEM34-yv
-